Revisiting the estrogen receptor pathway and its role in endocrine therapy for postmenopausal women with estrogen receptor-positive metastatic breast cancer

Breast Cancer Research and Treatment
Gayathri Nagaraj, Cynthia X Ma

Abstract

Endocrine therapy (ET) is the most commonly administered first-line systemic therapy for estrogen receptor-positive (ER+) metastatic breast cancer (MBC). Manipulation of hormone levels was one of the earliest ET approaches. However, treatment modalities have since evolved with the growing understanding of estrogen biosynthesis and ER biology. The current armamentarium of ET includes selective estrogen receptor modulation, aromatase inhibition, and selective estrogen receptor downregulation. However, intrinsic or acquired resistance to ET is frequently observed. Significant strides have been made in recent years in our understanding of the mechanisms of resistance to ET, and several targeted approaches including inhibitors against the phosphatidylinositol 3-kinase/mammalian target of rapamycin (PI3K/mTOR) pathway and cyclin-dependent kinase 4/6 (CDK4/6) have shown great promise. The mTOR inhibitor, everolimus, is already in clinical use for the treatment of resistant ER+MBC. However, multiple levels of evidence indicate that ER signaling remains as an important therapeutic target even in the resistance setting, providing the rationale for sequencing multiple lines and combinations of ET. In addition, recurrent mutations in estro...Continue Reading

References

Jun 24, 2000·Molecular and Cellular Biology·J Font de Mora, M Brown
Nov 1, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·I VergoteM von Euler
Nov 15, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J M NabholtzM von Euler
Feb 13, 2001·The Journal of Steroid Biochemistry and Molecular Biology·P J KushnerP Webb
Feb 13, 2001·European Journal of Biochemistry·D Roymans, H Slegers
Sep 25, 2001·Journal of Applied Physiology·E R Levin
Nov 1, 2001·Annual Review of Cell and Developmental Biology·R KatsoM D Waterfield
Jun 29, 2002·Molecular and Cellular Endocrinology·Takako SakamotoShin-ichi Hayashi
Aug 15, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A HowellC Morris
Oct 3, 2002·Journal of the National Cancer Institute·Richard R Love, John Philips
Jun 13, 2003·The New England Journal of Medicine·Ian E Smith, Mitch Dowsett
Dec 23, 2003·Best Practice & Research. Clinical Endocrinology & Metabolism·W R Miller
Mar 16, 2004·Science·Yardena SamuelsVictor E Velculescu
Apr 20, 2004·British Journal of Cancer·C K OsborneR I Nicholson
Jun 17, 2004·Journal of the National Cancer Institute·Jiang ShouRachel Schiff
Jul 16, 2004·Cancer Biology & Therapy·Kurtis E BachmanBen Ho Park
Mar 10, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C Kent Osborne, Rachel Schiff
Mar 15, 2005·American Journal of Clinical Pathology·Mehrdad NadjiAzorides R Morales
Jan 18, 2006·Cancer Letters·Lionel M L Chow, Suzanne J Baker
Sep 21, 2006·Journal of the National Cancer Institute·Davide MauriJohn P A Ioannidis
Oct 14, 2006·Breast Cancer Research and Treatment·William R MillerMark Verrill
Nov 23, 2006·The Journal of Steroid Biochemistry and Molecular Biology·A BrodieD Jelovac
Aug 4, 2007·The Oncologist·John F R Robertson
Mar 21, 2008·Breast Cancer Research and Treatment·Philippe L BedardMark Clemons
Jul 12, 2008·Molecular Endocrinology·Zeynep Madak-ErdoganBenita S Katzenellenbogen
Aug 13, 2008·Journal of the National Cancer Institute·Abenaa M BrewsterFrancisco J Esteva
Dec 9, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·P E Lønning
Jul 25, 2009·Nature Reviews. Cancer·Jeffrey A Engelman

❮ Previous
Next ❯

Citations

Sep 9, 2015·Endocrine-related Cancer·Penn Muluhngwi, Carolyn M Klinge
Dec 20, 2015·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·J GaviláM Martin
Nov 27, 2015·Pathology Oncology Research : POR·Xiaojuan WuRong Ma
Aug 12, 2015·Future Oncology·Anna S Berghoff, Matthias Preusser
Aug 23, 2016·Expert Review of Clinical Pharmacology·Francesca PoggioLucia Del Mastro
Oct 21, 2016·Iranian Journal of Cancer Prevention·Sanaz TabarestaniMohammad Esmaeil Akbari
Nov 1, 2016·Breast Cancer : the Journal of the Japanese Breast Cancer Society·V L MaruthanilaJibon Kotoky
Nov 12, 2015·Therapeutic Advances in Medical Oncology·Tomas Reinert, Carlos H Barrios
Jan 13, 2018·Reproduction : the Official Journal of the Society for the Study of Fertility·Bo Yoon ChangSung Yeon Kim
Feb 17, 2018·Therapeutic Advances in Medical Oncology·Rodica Di Lorenzo, Manmeet S Ahluwalia
Apr 30, 2017·Journal of Hematology & Oncology·Xichun HuMinhao Fan
Mar 15, 2019·Breast Cancer Research : BCR·Brett L EckerLewis A Chodosh
Apr 15, 2020·Cancers·Abdulaziz B Hamid, Ruben C Petreaca
Jan 23, 2021·Journal of Mammary Gland Biology and Neoplasia·Nina PetrovićMilica Nedeljković
Feb 3, 2016·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Amy M FowlerFarrokh Dehdashti

❮ Previous
Next ❯

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Related Papers

The American Journal of Pathology
Ali MohamedCynthia X Ma
Molecular and Cellular Endocrinology
Carlo PalmieriSacha J Howell
The New England Journal of Medicine
José BaselgaGabriel N Hortobagyi
© 2021 Meta ULC. All rights reserved